Verdiperstat ( DrugBank: Verdiperstat )
3 diseases
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 2 | Amyotrophic lateral sclerosis | 2 |
| 17 | Multiple system atrophy | 7 |
| 127 | Frontotemporal lobar degeneration | 1 |
2. Amyotrophic lateral sclerosis
Clinical trials : 624 / Drugs : 611 - (DrugBank : 160) / Drug target genes : 172 - Drug target pathways : 225
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04436510 (ClinicalTrials.gov) | July 28, 2020 | 1/6/2020 | HEALEY ALS Platform Trial - Regimen B Verdiperstat | HEALEY ALS Platform Trial - Regimen B Verdiperstat | Amyotrophic Lateral Sclerosis | Drug: Matching Placebo;Drug: Verdiperstat | Merit E. Cudkowicz, MD | Biohaven Pharmaceuticals, Inc. | Active, not recruiting | 18 Years | N/A | All | 167 | Phase 2/Phase 3 | United States |
| 2 | NCT04297683 (ClinicalTrials.gov) | July 14, 2020 | 3/3/2020 | HEALEY ALS Platform Trial - Master Protocol | HEALEY ALS Platform Trial | Amyotrophic Lateral Sclerosis | Drug: Zilucoplan;Drug: Verdiperstat;Drug: CNM-Au8;Drug: Pridopidine;Drug: SLS-005 Trehalose | Merit E. Cudkowicz, MD | Massachusetts General Hospital | Recruiting | 18 Years | N/A | All | 800 | Phase 2/Phase 3 | United States |
17. Multiple system atrophy
Clinical trials : 118 / Drugs : 163 - (DrugBank : 49) / Drug target genes : 61 - Drug target pathways : 112
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04616456 (ClinicalTrials.gov) | December 30, 2020 | 26/10/2020 | Effect of Verdiperstat on Microglial Activation in Well-characterized MSA Patients | Effect of Verdiperstat on Microglial Activation in Well-characterized MSA Patients | Multiple System Atrophy;Multiple System Atrophy, Cerebellar Variant;Multiple System Atrophy, Parkinson Variant (Disorder);Multiple System Atrophy (MSA) With Orthostatic Hypotension | Drug: [F-18]PBR06;Drug: Verdiperstat | Brigham and Women's Hospital | Biohaven Pharmaceuticals, Inc. | Active, not recruiting | 18 Years | N/A | All | 25 | Early Phase 1 | United States |
| 2 | EUCTR2019-001100-38-IT (EUCTR) | 19/02/2020 | 26/01/2021 | A study to assess whether a drug called BHV-3241 works and is safe to use in people with Multiple System Atrophy (M-STAR Study) | Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of BHV-3241 in Subjects with Multiple System Atrophy (M-STAR Study) - M-STAR Study | Multiple System Atrophy MedDRA version: 21.1;Level: PT;Classification code 10064060;Term: Multiple system atrophy;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: BHV-3241 Product Code: [/] INN or Proposed INN: Verdiperstat | Biohaven Pharmaceuticals, Inc. | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 252 | Phase 3 | France;United States;Austria;Germany;United Kingdom;China;Italy | ||
| 3 | EUCTR2019-001100-38-DE (EUCTR) | 07/01/2020 | 07/10/2019 | A study to assess whether a drug called BHV-3241 works and is safe to use in people with Multiple System Atrophy (M-STAR Study) | Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of BHV-3241 in Subjects with Multiple System Atrophy (M-STAR Study) | Multiple System Atrophy MedDRA version: 21.1;Level: PT;Classification code 10064060;Term: Multiple system atrophy;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: BHV-3241 INN or Proposed INN: Verdiperstat | Biohaven Pharmaceuticals, Inc | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 422 | Phase 3 | United States;France;Austria;Germany;United Kingdom;Italy;China | ||
| 4 | EUCTR2019-001100-38-AT (EUCTR) | 20/12/2019 | 29/10/2019 | A study to assess whether a drug called BHV-3241 works and is safe to use in people with Multiple System Atrophy (M-STAR Study) | Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of BHV-3241 in Subjects with Multiple System Atrophy (M-STAR Study) | Multiple System Atrophy MedDRA version: 21.1;Level: PT;Classification code 10064060;Term: Multiple system atrophy;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: BHV-3241 INN or Proposed INN: Verdiperstat | Biohaven Pharmaceuticals, Inc | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 422 | Phase 3 | United States;France;Austria;Germany;United Kingdom;Italy;China | ||
| 5 | EUCTR2019-001100-38-FR (EUCTR) | 13/12/2019 | 03/10/2019 | A study to assess whether a drug called BHV-3241 works and is safe to use in people with Multiple System Atrophy(M-STAR Study) | Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of BHV-3241 in Subjects with Multiple System Atrophy (M-STAR Study) | Multiple System Atrophy MedDRA version: 21.1;Level: PT;Classification code 10064060;Term: Multiple system atrophy;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: BHV-3241 INN or Proposed INN: Verdiperstat | Biohaven Pharmaceuticals, Inc | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 252 | Phase 3 | United States;France;Austria;Germany;Italy;United Kingdom | ||
| 6 | EUCTR2019-001100-38-GB (EUCTR) | 06/12/2019 | 11/10/2019 | A study to assess whether a drug called BHV-3241 works and is safe to use in people with Multiple System Atrophy(M-STAR Study) | Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of BHV-3241 in Subjects with Multiple System Atrophy (M-STAR Study) | Multiple System Atrophy MedDRA version: 21.1;Level: PT;Classification code 10064060;Term: Multiple system atrophy;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: BHV-3241 INN or Proposed INN: Verdiperstat | Biohaven Pharmaceuticals, Inc | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 422 | Phase 3 | United States;France;Austria;Germany;Italy;United Kingdom | ||
| 7 | NCT03952806 (ClinicalTrials.gov) | July 29, 2019 | 15/5/2019 | Study of BHV-3241 in Subjects With Multiple System Atrophy | A Randomized, Double-Blind, Placebo-Controlled, Parallel- Group Study to Evaluate the Efficacy and Safety of BHV-3241 in Subjects With Multiple System Atrophy (M-STAR Study) | Multiple System Atrophy | Drug: Verdiperstat;Drug: Placebo | Biohaven Pharmaceuticals, Inc. | NULL | Active, not recruiting | 40 Years | 80 Years | All | 336 | Phase 3 | United States;Austria;France;Germany;Italy;United Kingdom |
127. Frontotemporal lobar degeneration
Clinical trials : 89 / Drugs : 104 - (DrugBank : 33) / Drug target genes : 40 - Drug target pathways : 117
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05184569 (ClinicalTrials.gov) | January 20, 2022 | 17/12/2021 | Veri-T: A Trial of Verdiperstat in Patients With svPPA Due to TDP-43 Pathology | Phase 1, Randomized, Double-Blind, Placebo-Controlled, Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy Study of Oral Verdiperstat (BHV-3241) in Patients With Semantic Variant Primary Progressive Aphasia (svPPA) Due to TDP-43 Pathology | Semantic Dementia | Drug: Verdiperstat | Peter Ljubenkov, MD | National Institutes of Health (NIH);Alzheimer's Association;National Institute on Aging (NIA) | Not yet recruiting | 18 Years | 85 Years | All | 64 | Phase 1 | NULL |